401522-11-0

Usage

Uses

Used in Pharmaceutical Industry:
2-[3-(pyridin-4-yl)-1H-pyrazol-1-yl]ethanol is used as a pharmaceutical agent for its anti-inflammatory properties, helping to reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
Used in Cancer Research and Treatment:
In the field of oncology, 2-[3-(pyridin-4-yl)-1H-pyrazol-1-yl]ethanol is used as an anti-cancer agent, showing promise in inhibiting the growth and proliferation of cancer cells. Its potential to target specific cancer pathways makes it a candidate for further research and development in cancer therapies.
Used in Antimicrobial Applications:
2-[3-(pyridin-4-yl)-1H-pyrazol-1-yl]ethanol is utilized as an antimicrobial agent, effective against a range of microorganisms. Its ability to combat infections and resist microbial growth is valuable in the development of new antibiotics and antifungal agents.
Used in Organic Synthesis:
As a key intermediate in organic synthesis, 2-[3-(pyridin-4-yl)-1H-pyrazol-1-yl]ethanol is used as a building block for the creation of more complex molecules and compounds, contributing to the advancement of chemical research and the development of new materials and pharmaceuticals.

Upstream product

• 96-49-1 [1,3]-dioxolan-2-one 
• 17784-60-0 4-(1H-pyrazol-3-yl)pyridine 
• 109-84-2 2-hydroxyethylhydrazine 
• 123367-27-1 (E)-3-(dimethylamino)-1-(pyridin-4-yl)prop-2-en-1-one 

Downstream Products

• 401522-15-4 C₆₀H₈₆N₄O₁₆S 

Relevant academic research and scientific papers

RAF INHIBITOR COMPOUNDS AND METHODS

Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Novel ketolide antibiotics with a fused five-membered lactone ring - Synthesis, physicochemical and antimicrobial properties

In an effort to find novel semisynthetic macrolides with extended antibacterial spectrum and improved activity we prepared a series of compounds based on commercially available clarithromycin, a potent and safe antimicrobial agent of outstanding clinical and commercial interest. According to the literature, improvement of antibacterial activity of erythromycin type antibiotics can be achieved by introduction of fused heterocycles such as cyclic carbonates or carbamates at positions 11 and 12 (such as in telithromycin). In the course of the work presented here, a similar, hitherto unprecedented set of compounds bearing a five-membered lactone ring fused to positions 11 and 12 was prepared based on carbon-carbon bond formation via intramolecular Michael addition of a [(hetero)arylalkylthio]acetic acid ester enolate to an α,β-unsaturated ketone as the key step. Some of the ketolide compounds described in this paper were highly active against a representative set of erythromycin sensitive and erythromycin resistant test strains. The best compound showed a similar antimicrobial spectrum and comparable activity in vitro as well as in vivo as telithromycin. Furthermore, some physicochemical properties of these compounds were determined and are presented here. On the basis of these results, the novel ketolide lactones presented in this paper emerged as valuable lead compounds with comparable properties as the commercial ketolide antibacterial telithromycin (KetekTM).

Macrolides with antibacterial activity

The invention provides new macrolides antibiotics of formula (I) with improved biological properties and improved stability formula (I): wherein R1 is hydrogen, cyano, —S(L)mR2, —S(O)(L)mR2, or —S(O)